全球对比增强型乳房 X 光检查市场规模、份额、成长分析，按应用（筛检和诊断）、最终用户（医院、诊断中心）- 2024-2031 年产业预测

Global Contrast Enhanced Mammography Market Size, Share, Growth Analysis, By Applications(Screening and Diagnosis), By End User(Hospital, Diagnostic Centres) - Industry Forecast 2024-2031

出版日期: 2024年04月29日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022 年，全球增强型乳房X 光摄影市场规模为18.4 亿美元，预计将从2023 年的19.4 亿美元成长到2031 年的29.2 亿美元，预测期内（2024-2031 年）复合年增长率为5.28 %

对比增强乳房 X 光检查 (CEM) 采用双能量方法，结合了数位乳房 X 光检查与静脉注射显影剂的优点。与单独的全视野数位乳房 X 光摄影 (FFDM) 以及 FFDM 与超音波相结合在诊断环境中检测乳癌时，CEM 表现出更高的灵敏度。鑑于全球乳癌发生率不断上升，对比增强乳房X光检查（CEM）已成为广泛采用且流行的技术。多种因素会导致乳癌风险增加，包括年龄增长、肥胖、过量饮酒、乳癌家族史、先前接触过辐射、生育史（例如首次月经和分娩的年龄）、吸烟和停经后荷尔蒙疗法。大多数乳癌病例主要影响女性，影响很大一部分人口，通常起源于乳房组织。乳癌表现为多种症状，包括乳房肿块、乳房大小和形状的改变、乳头溢液以及皮肤变化，如搔痒、鳞屑和发红。此外，这种疾病的进展可能会导致其他症状，如骨痛、淋巴结肿胀、呼吸困难等，这表明疾病正在蔓延。因此，全球乳癌盛行率的增加成为市场扩张的催化剂。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2023 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率 (%), 2023

主要公司简介

Hologic Inc.
GE Healthcare
Siemens Healthineers AG
Koninklijke Philips NV
Fujifilm Holdings Corporation
Dilon Technologies Inc.
Planmed Oy
Metaltronica SpA
CMR Naviscan Corporation
General Medical Merate SpA
Delphinus Medical Technologies Inc.
Micrima Limited
KUB Technologies Inc.
Aurora Imaging Technology Inc.
Carestream Health Inc.
Planmed Oy
Zebra Medical Vision Ltd.
Volpara Health Technologies Ltd.
iCAD Inc.
Agfa-Gevaert NV
In 2021, Hologic, Inc. announced the launch of its new CEM technology, the Quantra 3.0 Breast Density Assessment software, which uses artificial intelligence to provide more accurate and consistent breast density measurements.
In 2021, Siemens Healthineers announced the launch of its new MAMMOMAT Revelation with 3D biopsy technology, which combines CEM, 3D mammography,, biopsy in a single exam. The system is designed to improve accuracy, and reduce patient discomfort.

简介目录

Product Code: SQMIG35G2123

Global contrast enhanced mammography market size was valued at USD 1.84 billion in 2022 and is poised to grow from USD 1.94 billion in 2023 to USD 2.92 billion by 2031, at a CAGR of 5.28% during the forecast period (2024-2031)

Utilizing a dual-energy approach, contrast-enhanced mammography (CEM) combines the advantages of digital mammography with intravenous contrast administration. CEM exhibits higher sensitivity compared to full-field digital mammography (FFDM) alone and FFDM coupled with ultrasound in the detection of breast cancer within diagnostic settings. Given the escalating global incidence of breast cancer, contrast enhanced mammography (CEM) has emerged as a widely adopted and prevalent technique. Various factors contribute to the increased risk of breast cancer, including advancing age, obesity, excessive alcohol consumption, family history of breast cancer, past exposure to radiation, reproductive history (such as age at first menstruation and childbirth), tobacco usage, and postmenopausal hormone therapy. The majority of breast cancer cases predominantly affect females, impacting a significant portion of the population, usually originating in breast tissues. Breast cancer manifests through various symptoms, including breast lumps, alterations in breast size and shape, nipple discharge, as well as skin changes like itchiness, scaliness, and redness. Moreover, the progression of this disorder may result in additional symptoms such as bone pain, lymph node swelling, breathing difficulties, among others, signifying the spread of the disease. Consequently, the increasing prevalence of breast cancer globally serves as a catalyst for the expansion of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global contrast enhanced mammography market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contrast Enhanced Mammography Market Segmental Analysis

Global contrast enhanced mammography market is segmented based on applications, end user, and region. By applications, the market is segmented into screening, and diagnosis. By end user, the market is segmented into hospital, diagnostic centres, specialty clinics, and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Contrast Enhanced Mammography Market

The primary driver of market growth is the increasing prevalence of breast cancer, which ranks as the most frequently diagnosed cancer among women globally. Early diagnosis significantly enhances the effectiveness of breast cancer treatment. Typically, patients undergo a combination of surgical procedures, radiation therapy, and medications like hormone therapy, chemotherapy, and targeted biological therapy to address microscopic cancer cells that may have spread from the original tumor. These treatments play a crucial role in halting the growth and spread of cancer, ultimately saving lives.

Restraints in the Global Contrast Enhanced Mammography Market

Contrast-enhanced mammography represents a newer technology in the field, accompanied by higher costs compared to traditional mammography. The expenses involved in acquiring equipment, materials, and providing necessary training for contrast-enhanced mammography pose significant barriers to its widespread adoption. Additionally, the availability of contrast-enhanced mammography remains limited, with a scarcity of facilities offering this technology, particularly in rural or remote areas. Regulatory approval is a prerequisite before contrast-enhanced mammography can be integrated into clinical practice, a process known for its lengthiness and expense, potentially delaying the technology's market entry. Furthermore, despite promising outcomes demonstrated in clinical studies, the absence of long-term data on its efficacy and safety may instill hesitation among healthcare providers regarding its adoption until more robust evidence becomes available.

Market Trends of the Global Contrast Enhanced Mammography Market

Each year witnesses a surge in breast cancer cases among women, driving the expansion of the market and the proliferation of available treatments. Advanced technologies have revolutionized breast cancer diagnostics, offering enhanced techniques for detection. These sophisticated technologies have significantly improved performance metrics such as efficiency, accuracy, efficacy, reliability, and speed of results, thereby facilitating early detection and intervention.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Contrast Enhanced Mammography Market by Applications

Market Overview
Screening and Diagnosis

Global Contrast Enhanced Mammography Market by End User

Market Overview
Hospital
Diagnostic Centres
Specialty Clinics
Others

Global Contrast Enhanced Mammography Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Hologic Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koninklijke Philips N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Holdings Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dilon Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Planmed Oy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Metaltronica S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CMR Naviscan Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
General Medical Merate S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delphinus Medical Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Micrima Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KUB Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurora Imaging Technology Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carestream Health Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Planmed Oy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zebra Medical Vision Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Volpara Health Technologies Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iCAD Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agfa-Gevaert NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In 2021, Hologic, Inc. announced the launch of its new CEM technology, the Quantra 3.0 Breast Density Assessment software, which uses artificial intelligence to provide more accurate and consistent breast density measurements.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In 2021, Siemens Healthineers announced the launch of its new MAMMOMAT Revelation with 3D biopsy technology, which combines CEM, 3D mammography, and biopsy in a single exam. The system is designed to improve accuracy and reduce patient discomfort.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments